Bedrijfsoverzicht
Outset Medical, Inc. is a specialized medical technology enterprise focused on the development and provision of hemodialysis systems specifically designed for use within the United States. The company's core offering, the Tablo Hemodialysis System, represents a technological advancement in dialysis care by integrating a compact console with on-demand dialysate production and water purification capabilities directly into a unified unit. Operating within the Healthcare sector and the Medical Devices industry, the firm leverages this integrated approach to address the logistical challenges of traditional hemodialysis infrastructure. With a market capitalization of $76.91M, annual revenue of $119.48M, and an employee base of 310 individuals, the company operates as a mid-sized entity in a capital-intensive industry. These valuation and revenue figures suggest that while the firm possesses significant cash reserves relative to its size, its current market valuation reflects the high-risk profile often associated with companies developing specialized medical equipment that has not yet achieved consistent profitability.
Financiële gezondheid
The company reported a revenue of $119.48M over the trailing twelve months, yet this top-line figure masks a net income of -$81.653M and an EBITDA of -$62.373M, revealing a substantial gap between gross revenue generation and net profitability. This discrepancy highlights a cost structure where operating expenses, research and development costs, or interest obligations significantly outpace gross margins, resulting in a net loss that is more than double the negative EBITDA. The free cash flow stands at -$21.34625M, indicating that the company is currently burning cash rather than generating liquidity, which limits its immediate financial flexibility to fund operations without external capital injections. Despite these negative operational metrics, the balance sheet contains $168.95M in cash against $101.25M in debt, creating a net cash position that provides a buffer against short-term liquidity pressures. The debt-to-equity ratio is recorded at 79.75, suggesting a highly leveraged capital structure where debt obligations are substantial relative to shareholders' equity. However, the current ratio of 6.67 indicates a very strong short-term liquidity position, as current assets are more than six times the value of current liabilities, ensuring the ability to meet immediate obligations. Return on Equity is -106.2% and Return on Assets is -15.4%, metrics that demonstrate management has not yet achieved positive returns on the capital deployed or the assets utilized in the business. These negative return figures underscore the company's current phase of investment, where profitability has not been realized despite significant asset accumulation and revenue generation.
Waarderingsbeoordeling
Valuation metrics for Outset Medical, Inc. present a complex picture given the lack of traditional earnings multiples. The trailing twelve-month P/E ratio is listed as N/A due to the absence of net income, while the forward P/E is calculated at -1.79, a figure that implies analysts are projecting continued negative earnings rather than a transition to profitability. The price-to-book ratio stands at 0.60, indicating that the market values the company at 60% of its book value, which suggests a discount rather than a premium over the net asset value recorded on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 0.64 and the EV/EBITDA of -0.15 further reflect the challenges in applying standard profitability multiples to a company with negative earnings. The stock has exhibited significant volatility over the past year, trading between a 52-week low of $3.00 and a 52-week high of $21.98. Without a specific current share price provided in the data, the exact percentage deviation from the 52-week high cannot be calculated, but the wide range of $18.98 between the high and low demonstrates extreme price sensitivity. The beta value of 1.96 indicates that the stock price is highly volatile, moving nearly twice as much as the broader market index during periods of fluctuation.
Growth & Income
Revenue growth for the trailing twelve months was -2.0%, while earnings growth is listed as N/A due to the lack of prior year net income data for comparison. The negative revenue growth suggests a contraction in sales or a shift in market dynamics, whereas the N/A earnings growth metric simply reflects the inability to calculate year-over-year changes without profitable baseline data. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning it retains all earnings to fund operations, research, and development rather than distributing income to shareholders. Consequently, the company reinvests its limited cash flow and existing capital reserves into its hemodialysis technology and operational scaling rather than providing an income stream to investors. The overall growth and income profile characterizes Outset Medical, Inc. as a high-risk, high-volatility investment with no current income generation and recent sales contraction.